EP2262771A1 - A method for the preparation of dabigatran - Google Patents

A method for the preparation of dabigatran

Info

Publication number
EP2262771A1
EP2262771A1 EP09719117A EP09719117A EP2262771A1 EP 2262771 A1 EP2262771 A1 EP 2262771A1 EP 09719117 A EP09719117 A EP 09719117A EP 09719117 A EP09719117 A EP 09719117A EP 2262771 A1 EP2262771 A1 EP 2262771A1
Authority
EP
European Patent Office
Prior art keywords
reaction
formula
compound
dabigatran
ethyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP09719117A
Other languages
German (de)
English (en)
French (fr)
Inventor
Josef Jirman
Jindrich Richter
Petr Lustig
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Zentiva KS
Original Assignee
Zentiva KS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zentiva KS filed Critical Zentiva KS
Publication of EP2262771A1 publication Critical patent/EP2262771A1/en
Withdrawn legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D213/00Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72Nitrogen atoms
    • C07D213/74Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals

Definitions

  • Dabigatran is an anticoagulant compound and it is used for treatment of thromboses, cardiovascular diseases, and the like.
  • the invention deals with a new method for the manufacture of 3-([2-[[(4-(N-n- hexyloxycarbonylcarbamimidoyl)phenylamino] -methyl] ] - 1 -methyl- 1 H-benzimidazole-5 - carbonyl]-pyridin-2-yl-amino)ethyl propionate of formula VIII
  • Hydrogen chloride is dissolved in an organic solvent selected, e.g., from the group of ethers, esters, ketones and alcohols. Diethylether appears to be the most suitable one.
  • the next production stage is reduction of the nitro group to the amino group.
  • the procedure according to the present invention is performed in a solvent mixture of ethanol and water.
  • the reagent is sodium dithionite. It is not necessary to operate at elevated pressure or very high temperature. This procedure is much less costly and more advantageous from the economic point of view.
  • Substance III enters the reaction in the hydrochloride form, which has a positive influence on the course of the reaction and purity of the product. Using the combination of changing the quality and composition of the starting substance and of the method of reduction of the nitro group it is possible to obtain product IV with a minimum content of impurities, i.e. less that 5%, preferably less than 1%.
  • compound VI is obtained in the form of a salt with oxalic acid.
  • This salt is simply re-purified by further crystallization, which provides the advanced intermediate VI in a yield that is acceptable for industrial production, approximately 80 to 90%.
  • This crystallization can be carried out from a polar protic organic solvent, preferably from lower Ci - C 5 alcohols, e.g. from ethyl alcohol.
  • the crude hydrochloride was crystallized from a mixture of denatured non-dried ethanol with acetonitrile 9:1.
  • Substance III was put into 1500 ml of the ethanol - water mixture 1 :1 and heated up to 50 °C. This way a solution was created to which solid sodium dithionite was added quickly and under intensive stirring. After the starting substance has reacted the reaction mixture was concentrated in a vacuum evaporator. After separation of oil the concentration was completed and the product was extracted with ethyl acetate. After its drying with sodium sulphate the solvent is evaporated. The product is obtained as a brown, very viscous liquid. Yield: 82 g (81.3%); HPLC: 95%
  • Substance V and l,l'-carbonyldiimidazole are put into a flask blown with an inert gas. 2000 ml of dry THF are added and the mixture is boiled under a reflux condenser with a calcium- chloride tube for 40 minutes. After 40 minutes a solution of substance IV in 330 ml of dry THF is added to the mixture and the mixture is boiled for another 5 hours. After expiration of this time period the reaction mixture is slightly cooled and THF is removed by distillation in vacuum. 1000 ml of glacial acetic acid are added to the honey-like brown residue and the resulting solution is boiled for 1 hour. The acid is distilled off and the produced residue is dissolved in dichloromethane (850 ml) and shaken with water. The separated organic layer is dried with sodium sulphate and the solvent is evaporated. A dark brown honey-like residue is obtained.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pyridine Compounds (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
EP09719117A 2008-03-14 2009-03-10 A method for the preparation of dabigatran Withdrawn EP2262771A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CZ2008-165A CZ305085B6 (cs) 2008-03-14 2008-03-14 Způsob přípravy dabigatranu
PCT/CZ2009/000037 WO2009111997A1 (en) 2008-03-14 2009-03-10 A method for the preparation of dabigatran

Publications (1)

Publication Number Publication Date
EP2262771A1 true EP2262771A1 (en) 2010-12-22

Family

ID=40627441

Family Applications (1)

Application Number Title Priority Date Filing Date
EP09719117A Withdrawn EP2262771A1 (en) 2008-03-14 2009-03-10 A method for the preparation of dabigatran

Country Status (6)

Country Link
US (1) US8394961B2 (ru)
EP (1) EP2262771A1 (ru)
CZ (1) CZ305085B6 (ru)
EA (1) EA018053B1 (ru)
UA (1) UA102248C2 (ru)
WO (1) WO2009111997A1 (ru)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014012880A1 (en) 2012-07-16 2014-01-23 Interquim, S.A. Process for the preparation of intermediates for the synthesis of dabigatran etexilate, and crystalline forms of said intermediates

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CZ2008669A3 (cs) * 2008-10-24 2010-05-05 Zentiva, A. S. Zpusob prípravy dabigatranu a jeho meziprodukty
MX2013000295A (es) 2010-07-09 2013-05-28 Esteve Quimica Sa Procedimiento de preparacion de un inhibidor especifico de la trombina.
JP2013531004A (ja) * 2010-07-09 2013-08-01 エステヴェ キミカ, エス.エー. トロンビン特異的インヒビターの調製のための中間体及び方法
EP2649060B1 (en) * 2010-12-06 2017-04-05 MSN Laboratories Limited Process for the preparation of benzimidazole derivatives and its salts
HUP1100244A2 (hu) * 2011-05-11 2012-11-28 Egis Gyogyszergyar Nyilvanosan Muekoedoe Reszvenytarsasag Gyógyszeripari intermedierek és eljárás elõállításukra
WO2013024384A1 (en) * 2011-08-12 2013-02-21 Alembic Pharmaceuticals Limited Improved process for preparation of dabigatran etexilate and its novel intermediate
US9273030B2 (en) 2012-04-02 2016-03-01 Msn Laboratories Private Limited Process for the preparation of benzimidazole derivatives and salts thereof
CN102911160B (zh) * 2012-06-29 2014-10-22 上海奥博生物医药技术有限公司 一种制备和纯化达比加群酯中间体的方法
MX350575B (es) 2012-09-27 2017-09-11 Bayer Cropscience Ag Procedimiento para la preparación de fenil y piridil pirrolidinas opcionalmente sustituidas.
US9533971B2 (en) 2012-10-29 2017-01-03 Biophore India Pharmaceuticals Pvt. Ltd Process for the synthesis of dabigatran and its intermediates
US10077251B2 (en) 2012-10-29 2018-09-18 Biophore India Pharmaceuticals Pvt. Ltd. Process for the synthesis of Dabigatran Etexilate and its intermediates
WO2015124764A1 (en) * 2014-02-24 2015-08-27 Erregierre S.P.A. Synthesis process of dabigatran etexilate mesylate, intermediates of the process and novel polymorph of dabigatran etexilate
WO2015128875A2 (en) * 2014-02-26 2015-09-03 Megafine Pharma (P) Ltd. A process for preparation of dabigatran etexilate mesylate and intermediates thereof
WO2015132794A1 (en) * 2014-03-06 2015-09-11 Symed Labs Limited Improved processes for the preparation of dabigatran etexilate using novel intermediates
CN103992241B (zh) * 2014-06-05 2016-08-24 雅本化学股份有限公司 N-取代苯基甘氨酸的制备方法
EP3165521B1 (en) 2014-07-03 2019-01-16 Shanghai Institute Of Pharmaceutical Industry Method of preparing dabigatran etexilate intermediate and intermediate compound
CN105461688B (zh) * 2014-08-26 2017-12-29 上海医药工业研究院 苯并咪唑化合物k的合成方法
CN108727334B (zh) * 2018-07-12 2020-10-30 江西国药有限责任公司 一种甲磺酸达比加群酯的生产工艺
CN109942434A (zh) * 2019-03-26 2019-06-28 山东世纪阳光科技有限公司 一种大红色基g的生产方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE121699A1 (es) * 1997-02-18 1999-12-08 Boehringer Ingelheim Pharma Heterociclos biciclicos disustituidos como inhibidores de la trombina
EP1609784A1 (de) * 2004-06-25 2005-12-28 Boehringer Ingelheim Pharma GmbH & Co.KG Verfahren zur Herstellung von 4-(Benzimidazolylmethylamino)-Benzamidinen
DE102005061623A1 (de) * 2005-12-21 2007-06-28 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verbessertes Verfahren zur Herstellung von 4-(Benzimidazolylmethylamino)-Benzamidinen und deren Salzen
EP1956018A1 (de) * 2007-02-06 2008-08-13 Boehringer Ingelheim Pharma GmbH & Co. KG Verfahren zur Herstellung eines Benzimidazolderivats

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO2009111997A1 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014012880A1 (en) 2012-07-16 2014-01-23 Interquim, S.A. Process for the preparation of intermediates for the synthesis of dabigatran etexilate, and crystalline forms of said intermediates

Also Published As

Publication number Publication date
EA018053B1 (ru) 2013-05-30
CZ305085B6 (cs) 2015-04-29
EA201001394A1 (ru) 2011-02-28
US8394961B2 (en) 2013-03-12
WO2009111997A1 (en) 2009-09-17
CZ2008165A3 (cs) 2009-09-23
UA102248C2 (ru) 2013-06-25
US20110082299A1 (en) 2011-04-07

Similar Documents

Publication Publication Date Title
US8394961B2 (en) Method for the preparation of dabigatran
CN102356063A (zh) 制备6-(7-((1-氨基环丙基)甲氧基)-6-甲氧基喹啉-4-基氧基)-n-甲基-1-萘甲酰胺的方法及其合成中间体
EP2346850A1 (en) A method for the preparation of dabigatran and its intermediates
CN105198821B (zh) 洛昔替尼的制备方法
CN102746288B (zh) 一种抗凝血药及其关键中间体的制备方法
CN106632033A (zh) 乐伐替尼的一种制备方法
CN104829590B (zh) 一种纯化曲格列汀的方法
EA036663B1 (ru) Способ получения азоксистробина
JP6174161B2 (ja) 2−アミノニコチン酸ベンジルエステル誘導体の製造方法
RU2470919C2 (ru) Способ получения соединения толуидина
US20190300484A1 (en) An improved process for the preparation of regorafenib
WO2011010579A1 (ja) 光学活性ニペコタミドの製造方法
KR100574350B1 (ko) 2-아미노피리딘 유도체의 제조방법
KR20200014305A (ko) 3-아릴 프로피온 아미드 화합물 및 3-아릴 프로피온산 에스테르 화합물의 제조 방법
CN103012264B (zh) 3‑取代氨基‑六氢‑1h‑氮杂环庚烷的拆分方法
WO2016116074A1 (en) A method of producing highly pure rilpivirine and its salts
CN107011254B (zh) 一种2-氨基-4-甲基吡啶的合成及其纯化方法
RU2409554C1 (ru) Способ получения 4-(3,4-диаминофенокси)бензойной кислоты
CN112939893A (zh) 一种4-(4-氨基苯基)-3-吗啉酮的合成方法
CN103804287B (zh) 一种2-氯异烟酸的制备方法
RU2481328C1 (ru) Способ получения нитраминопропионитрила
KR102719583B1 (ko) 테리플루노미드의 신규한 제조 공정
RU2722316C2 (ru) Новый способ получения терифлуномида
CN114560862A (zh) 一种吡咯并[1,2-a]喹喔啉-4(5h)-酮及其衍生物的合成方法
WO2021241725A1 (ja) 高純度のn-(5-メトキシ―2-フェノキシフェニル)メタンスルホンアミド及びその製造方法

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20100916

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO SE SI SK TR

AX Request for extension of the european patent

Extension state: AL BA RS

DAX Request for extension of the european patent (deleted)
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20151001